目的：观察乌司他丁对小儿体外循环（CPB）术后凝血功能的影响。方法：50例行心内直视修补术的单纯室间隔缺损患儿随机分为两组：乌司他丁组和对照组。乌司他丁组在CPB预充液中加入乌司他丁1.0×104 U/kg。选择肝素化前、CPB结束后1 h、6 h、24 h共4个时间点，检测患儿的凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、凝血酶时间（TT）等凝血指标。结果：与对照组比较，乌司他丁组PT在CPB结束后 1 h（18.7±0.7 s vs 15.5±0.5 s）及6 h（17.5±0.6 s vs 15.0±0.6 s）显著延长；APTT在CPB结束后6 h（38.7±3.1 s vs 35.3±3.1 s）及24 h（34.2±3.0 s vs 31.1±2.6 s）显著延长（P<0.05）。结论：乌司他丁可引起患儿CPB术后PT及APTT延长，影响凝血状态。
Abstract
OBJECTIVE: To study the effects of ulinastatin on coagulation in children who underwent open-heart surgery with cardiopulmonary bypass (CPB). METHODS: Fifty children who underwent open-heart surgery for ventricular septal defect were randomly divided into two groups: ulinastatin treatment and control. Before CPB, ulinastatin (1.0×104 U/kg) was added to CPB priming fluid only in the ulinastatin treatment group. Activated partial thromboplasin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen and international normalized ratio (INR) were measured both before and at 1 hr, 6 hrs and 24 hrs after CPB. RESULTS: The PT in the ulinastatin group was more prolonged than in the control group at 1 hr after CPB (18.7±0.7 s vs 15.5±0.5 s) and 6 hrs after CPB (17.5±0.6 s vs 15.0±0.6 s). The APTT in the ulinatatin group was also significantly more prolonged than in the control group at 6 hrs after CPB (38.7±3.1 s vs 35.3±3.1 s) and 24 hrs after CPB (34.2±3.0 s vs 31.1±2.6 s). CONCLUSIONS: Ulinastatin may prolong PT and APTT after CPB, and thus affects coagulation in children.
关键词
乌司他丁 /
凝血功能 /
体外循环 /
儿童
Key words
Ulinastatin /
Coagulation /
Cardiopulmonary bypass /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］雷宾峰，陈铭伍，冼磊，何巍，冯旭，周华富.乌司他丁对心脏不停跳心内直视术机体免疫功能的影响［J］.广西医科大学学报，2008，25（3）:381-383.
［2］王妍心，陈胜阳. 乌司他丁对儿童体外循环后肺的保护作用［J］. 实用儿科临床杂志，2011，26（11）：846-847.
［3］Nishiyama T, Yokoyama T, Yamashita K. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery［J］. J Anesth, 2006, 20 (3): 179-182.
［4］Kawamura T, Inada K, Akasaka N, Wakusawa R. Ulinastatin reduces elevation of cytokines and soluble adhesion molecules during cardiac surgery［J］. Can J Anaesth, 1996, 43 (5 Pt 1): 456-460.
［5］Pugia MJ, Valdes R Jr, Jortani SA. Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement［J］. Adv Clin Chem, 2007, 44: 223-245.
［6］Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent［J］. Biol Chem, 2003, 384 (5): 749-754.
［7］Nii A, Morishita H, Yamakawa T, Matsusue T, Hirose J, Miura T, et al. Design of variants of the second domain of urinary trypsin inhibitor (R-020) with increased factor Xa inhibitory activity［J］. J Biochem, 1994, 115（6）: 1107-1112.
［8］Ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor［J］. J Clin Invest, 1993, 92(3): 1207-1212.
PDF(894 KB)
